Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk. This evidence concerns the gene SLC5A1 and metabolic dysfunction-associated steatotic liver disease.